These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37674079)

  • 1. CD300ld on neutrophils is required for tumour-driven immune suppression.
    Wang C; Zheng X; Zhang J; Jiang X; Wang J; Li Y; Li X; Shen G; Peng J; Zheng P; Gu Y; Chen J; Lin M; Deng C; Gao H; Lu Z; Zhao Y; Luo M
    Nature; 2023 Sep; 621(7980):830-839. PubMed ID: 37674079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting polymorphonuclear myeloid-derived suppressor cells in the immunosuppressive tumor microenvironment for cancer immunotherapy.
    Li S; Long X
    MedComm (2020); 2024 Jul; 5(7):e602. PubMed ID: 38911064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
    Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
    Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
    J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression.
    Patel A; Oba T; Kajihara R; Yokoi T; Abrams SI; Ito F
    J Immunol; 2021 Sep; 207(5):1298-1309. PubMed ID: 34362833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD300ld to normalize the tumor microenvironment: an emerging insight in cancer immunotherapy.
    Zhang LZ; He X; Zhu HD
    MedComm (2020); 2024 Jul; 5(7):e607. PubMed ID: 38911066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma.
    Zhong LM; Liu ZG; Zhou X; Song SH; Weng GY; Wen Y; Liu FB; Cao DL; Liu YF
    Oral Oncol; 2019 Aug; 95():157-163. PubMed ID: 31345384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization.
    Groth C; Weber R; Lasser S; Özbay FG; Kurzay A; Petrova V; Altevogt P; Utikal J; Umansky V
    Int J Cancer; 2021 Nov; 149(9):1628-1638. PubMed ID: 34224592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment.
    Zhang Y; Guoqiang L; Sun M; Lu X
    Cancer Biol Med; 2020 Feb; 17(1):32-43. PubMed ID: 32296575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualization and quantification of
    Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
    Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL.
    Ferrer G; Jung B; Chiu PY; Aslam R; Palacios F; Mazzarello AN; Vergani S; Bagnara D; Chen SS; Yancopoulos S; Xochelli A; Yan XJ; Burger JA; Barrientos JC; Kolitz JE; Allen SL; Stamatopoulos K; Rai KR; Sherry B; Chiorazzi N
    Leukemia; 2021 Nov; 35(11):3163-3175. PubMed ID: 33935280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds with near infrared photoimmunotherapy enhances host immune response.
    Kato T; Fukushima H; Furusawa A; Okada R; Wakiyama H; Furumoto H; Okuyama S; Takao S; Choyke PL; Kobayashi H
    Oncoimmunology; 2022; 11(1):2152248. PubMed ID: 36465486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudoneutrophil Cytokine Sponges Disrupt Myeloid Expansion and Tumor Trafficking to Improve Cancer Immunotherapy.
    Li S; Wang Q; Shen Y; Hassan M; Shen J; Jiang W; Su Y; Chen J; Bai L; Zhou W; Wang Y
    Nano Lett; 2020 Jan; 20(1):242-251. PubMed ID: 31790598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
    Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
    Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer.
    Ugolini A; Tyurin VA; Tyurina YY; Tcyganov EN; Donthireddy L; Kagan VE; Gabrilovich DI; Veglia F
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion of Polymorphonuclear Myeloid-Derived Suppressor Cells in Patients With Gout.
    Zhong L; Li S; Wen Y; Zheng J; Liu F; Cao D; Liu Y
    Front Immunol; 2020; 11():567783. PubMed ID: 33154749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decidua-derived granulocyte macrophage colony-stimulating factor induces polymorphonuclear myeloid-derived suppressor cells from circulating CD15+ neutrophils.
    Li C; Chen C; Kang X; Zhang X; Sun S; Guo F; Wang Q; Kou X; Bai W; Zhao A
    Hum Reprod; 2020 Dec; 35(12):2677-2691. PubMed ID: 33067638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.
    Won H; Moreira D; Gao C; Duttagupta P; Zhao X; Manuel E; Diamond D; Yuan YC; Liu Z; Jones J; D'Apuzzo M; Pal S; Kortylewski M
    J Leukoc Biol; 2017 Aug; 102(2):423-436. PubMed ID: 28533357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.